Reviews Tamoxifen Citrate


No reviews yet.

Nolvadex Drug Description
NOLVADEX
(tamoxifen citrate) Tablets

WARNING
For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer: Serious and life-threatening events associated with NOLVADEX
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY-Clinical Studies - Reduction in Breast
Cancer Incidence In High Risk Women). Uterine malignancies consist of
both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20
for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per
1,000 women-years of 0.17 for NOLVADEX vs 0.4 for placebo)*. For stroke, the
incidence rate per 1,000 women-years was 1.43 for NOLVADEX vs 1.00 for placebo**.
For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75
for NOLVADEX versus 0.25 for placebo**.
Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential
risks of these serious events with women at high risk of breast cancer and women
with DCIS considering NOLVADEX to reduce their risk of developing breast cancer.

The benefits of NOLVADEX outweigh its risks in women already diagnosed with
breast cancer.
REFERENCES
*Updated long-term follow-up data (median length of follow-up
is 6.9 years) from NSABP P-1 study. See WARNINGS:
Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma.
**See Table 3 under CLINICAL PHARMACOLOGY-Clinical
Studies.

DRUG DESCRIPTION
NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are
for oral administration. NOLVADEX Tablets are available as:
10 mg Tablets
Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10
mg of tamoxifen.
20 mg Tablets
Each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20
mg of tamoxifen.
Inactive Ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol
and starch.
Chemically, NOLVADEX is the trans-isomer of a triphenylethylene derivative.
The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine
2 hydroxy-1,2,3- propanetricarboxylate (1:1). The structural and empirical formulas
are:








Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium
solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C,
it is 0.2 mg/mL.Last reviewed on RxList: 4/10/2008




Nolvadex Drug Description
NOLVADEX
(tamoxifen citrate) Tablets

WARNING
For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer: Serious and life-threatening events associated with NOLVADEX
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY-Clinical Studies - Reduction in Breast
Cancer Incidence In High Risk Women). Uterine malignancies consist of
both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20
for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per
1,000 women-years of 0.17 for NOLVADEX vs 0.4 for placebo)*. For stroke, the
incidence rate per 1,000 women-years was 1.43 for NOLVADEX vs 1.00 for placebo**.
For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75
for NOLVADEX versus 0.25 for placebo**.
Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential
risks of these serious events with women at high risk of breast cancer and women
with DCIS considering NOLVADEX to reduce their risk of developing breast cancer.

The benefits of NOLVADEX outweigh its risks in women already diagnosed with
breast cancer.
REFERENCES
*Updated long-term follow-up data (median length of follow-up
is 6.9 years) from NSABP P-1 study. See WARNINGS:
Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma.
**See Table 3 under CLINICAL PHARMACOLOGY-Clinical
Studies.

DRUG DESCRIPTION
NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are
for oral administration. NOLVADEX Tablets are available as:
10 mg Tablets
Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10
mg of tamoxifen.
20 mg Tablets
Each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20
mg of tamoxifen.
Inactive Ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol
and starch.
Chemically, NOLVADEX is the trans-isomer of a triphenylethylene derivative.
The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine
2 hydroxy-1,2,3- propanetricarboxylate (1:1). The structural and empirical formulas
are:








Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium
solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C,
it is 0.2 mg/mL.Last reviewed on RxList: 4/10/2008




Nolvadex Drug Description
NOLVADEX
(tamoxifen citrate) Tablets

WARNING
For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer: Serious and life-threatening events associated with NOLVADEX
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY-Clinical Studies - Reduction in Breast
Cancer Incidence In High Risk Women). Uterine malignancies consist of
both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20
for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per
1,000 women-years of 0.17 for NOLVADEX vs 0.4 for placebo)*. For stroke, the
incidence rate per 1,000 women-years was 1.43 for NOLVADEX vs 1.00 for placebo**.
For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75
for NOLVADEX versus 0.25 for placebo**.
Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential
risks of these serious events with women at high risk of breast cancer and women
with DCIS considering NOLVADEX to reduce their risk of developing breast cancer.

The benefits of NOLVADEX outweigh its risks in women already diagnosed with
breast cancer.
REFERENCES
*Updated long-term follow-up data (median length of follow-up
is 6.9 years) from NSABP P-1 study. See WARNINGS:
Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma.
**See Table 3 under CLINICAL PHARMACOLOGY-Clinical
Studies.

DRUG DESCRIPTION
NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are
for oral administration. NOLVADEX Tablets are available as:
10 mg Tablets
Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10
mg of tamoxifen.
20 mg Tablets
Each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20
mg of tamoxifen.
Inactive Ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol
and starch.
Chemically, NOLVADEX is the trans-isomer of a triphenylethylene derivative.
The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine
2 hydroxy-1,2,3- propanetricarboxylate (1:1). The structural and empirical formulas
are:








Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium
solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C,
it is 0.2 mg/mL.Last reviewed on RxList: 4/10/2008




Nolvadex Drug Description
NOLVADEX
(tamoxifen citrate) Tablets

WARNING
For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer: Serious and life-threatening events associated with NOLVADEX
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY-Clinical Studies - Reduction in Breast
Cancer Incidence In High Risk Women). Uterine malignancies consist of
both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20
for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per
1,000 women-years of 0.17 for NOLVADEX vs 0.4 for placebo)*. For stroke, the
incidence rate per 1,000 women-years was 1.43 for NOLVADEX vs 1.00 for placebo**.
For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75
for NOLVADEX versus 0.25 for placebo**.
Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential
risks of these serious events with women at high risk of breast cancer and women
with DCIS considering NOLVADEX to reduce their risk of developing breast cancer.

The benefits of NOLVADEX outweigh its risks in women already diagnosed with
breast cancer.
REFERENCES
*Updated long-term follow-up data (median length of follow-up
is 6.9 years) from NSABP P-1 study. See WARNINGS:
Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma.
**See Table 3 under CLINICAL PHARMACOLOGY-Clinical
Studies.

DRUG DESCRIPTION
NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are
for oral administration. NOLVADEX Tablets are available as:
10 mg Tablets
Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10
mg of tamoxifen.
20 mg Tablets
Each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20
mg of tamoxifen.
Inactive Ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol
and starch.
Chemically, NOLVADEX is the trans-isomer of a triphenylethylene derivative.
The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine
2 hydroxy-1,2,3- propanetricarboxylate (1:1). The structural and empirical formulas
are:








Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium
solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C,
it is 0.2 mg/mL.Last reviewed on RxList: 4/10/2008




Nolvadex Drug Description
NOLVADEX
(tamoxifen citrate) Tablets

WARNING
For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer: Serious and life-threatening events associated with NOLVADEX
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY-Clinical Studies - Reduction in Breast
Cancer Incidence In High Risk Women). Uterine malignancies consist of
both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20
for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per
1,000 women-years of 0.17 for NOLVADEX vs 0.4 for placebo)*. For stroke, the
incidence rate per 1,000 women-years was 1.43 for NOLVADEX vs 1.00 for placebo**.
For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75
for NOLVADEX versus 0.25 for placebo**.
Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential
risks of these serious events with women at high risk of breast cancer and women
with DCIS considering NOLVADEX to reduce their risk of developing breast cancer.

The benefits of NOLVADEX outweigh its risks in women already diagnosed with
breast cancer.
REFERENCES
*Updated long-term follow-up data (median length of follow-up
is 6.9 years) from NSABP P-1 study. See WARNINGS:
Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma.
**See Table 3 under CLINICAL PHARMACOLOGY-Clinical
Studies.

DRUG DESCRIPTION
NOLVADEX® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are
for oral administration. NOLVADEX Tablets are available as:
10 mg Tablets
Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10
mg of tamoxifen.
20 mg Tablets
Each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20
mg of tamoxifen.
Inactive Ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol
and starch.
Chemically, NOLVADEX is the trans-isomer of a triphenylethylene derivative.
The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine
2 hydroxy-1,2,3- propanetricarboxylate (1:1). The structural and empirical formulas
are:








Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium
solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C,
it is 0.2 mg/mL.Last reviewed on RxList: 4/10/2008





Other reviews about Tamoxifen Citrate on wordpress

Metabolic syndrome possible drug targets
  by brinkman
Ongoing studies by researchers at UT Southwestern Medical Center and other institutions have uncovered the biochemical basis of many of the factors contributing to what is known as […]


Nolvadex - Tamoxifen Citrate Steroids Profies
  by 258s20r5h
Nolvadex is useful in a diet because it helps to burn fat. If Al Nolvadex has no direct impact slimming antiestrogenic effects contributes to the maintenance of estrogen […]


EUSA Pharma
  by Sitemaster
Cancer Drugs in Development CYT-500 Marketed Oncology Drugs Artificial saliva (Caphosol®) Capromab pendetide (ProstaScint®) Crisantaspase (Erwinase®) [not filed for approval in the USA] L-Asparaginase (Kidrolase®) [not filed for approval in the USA] Samarium Sm-153 lexidronam injection (Quadramet®) Tamoxifen citrate, oral […]


there are no words...
  by B
The Food and Drug Administration has issued an alert about two pharmacies in Baltimore suspected of distributing expired or counterfeit drugs. The agency said patients who have received […]


What can WE believe?
  by mynoduesp
What can we believe about Cancer and other diseases?  Belief shapes action so then what can we do with our Belief?  Do you believe that simple things like […]


U.S. DOJ files amicus brief on reverse payment settlements
  by Juha Vesala
On 6 July 2009 the U.S. Department of Justice filed an amicus brief in a reverse payment settlement case on appeal before the 2nd Circuit (In re Ciprofloxacin Hydrochloride […]


Anabolic Steroid Cycles
  by anabolictoday
A steroid cycle is the amount of time a athlete is on a specific anabolic steroid. Steroid cycles vary from person to person but they usually last from […]


Nolvadex in Bodybuilding Using Tamoxifen on an Anabolic Steroid Cycle
  by cracklinbread300
Dear Friend and Fellow Athelete, Nolvadex (Tamoxifen Citrate) In bodybuilding, Nolvadex (Tamoxifen Citrate) is used as both an anabolic steroid cycle ancillary drug and as recovery or […]


U.S. Court of Appeals for the Second Circuit invites petitions for en banc rehearing in reverse payment settlement case
  by Juha Vesala
On 29 April 2010 the U.S. Court of Appeals for the Second Circuit affirmed a lower court decision finding that reverse payment settlements did not violate antitrust laws, as […]


Sometimes overwhelmed night, elected Basin Guilvinec had met in 2006
  by zyonfcfv
Sometimes overwhelmed night, elected Basin Guilvinec had met in 2006. Since then, work carried out by Network with youth starting to bear fruit. The observation is done every […]



Other reviews about Tamoxifen Citrate on web:

Tamoxifen is an antagonist of the estrogen receptor in breast tissue. In other tissues such as the endometrium, it behaves as an agonist, hence taxoxifen may be characterized ... Tamoxifen - Wikipedia, the free encyclopedia


DESCRIPTION Tamoxifen Citrate Tablets, a nonsterodial antiestrogen, are for oral administration and contain 15.2 mg of Tamoxifen Citrate (equivalent to 10 mg of tamoxifen). Tamoxifen Citrate


Comprehensive and trusted information about Tamoxifen citrate - plus advice on 24,000 other FDA approved drugs and medications from Drugs.com. Tamoxifen citrate patient advice including side effects


Learn about the prescription medication Nolvadex (Tamoxifen Citrate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Nolvadex (Tamoxifen Citrate) Drug Information: Uses, Side Effects ...


Nolvadex is commonly referred to in quite a few ways as a SERM Selective Estrogen Receptor Modulator, as an anti-estrogen that is actually incorrect, as we will later see, and ... Nolvadex tamoxifen citrate - Anabolic SteroidProfiles - Steroid . com


Tamoxifen Citrate is an anti-estrogen used to treat or prevent breast cancer. Side effects and interactions are available at drugstore.com; plus get home delivery from a trusted ... Tamoxifen Citrate - drugstore.com. Low prices, side effects ...


This page contains brief information about tamoxifen citrate and a collection of links to more information about the use of this drug, related news and research results, and ... Tamoxifen Citrate - National Cancer Institute


Tamoxifen Citrate Review - Find Out All The Information You Need Tamoxifen Citrate Review


Women taking Tamoxifen to decrease the risk of developing breast cancer have developed cancer of the uterus, stroke, and blood clots in the lung. Some of these events have ... Nolvadex (Tamoxifen Citrate) - 10mg Generic Tablets


Tamoxifen Citrate professional patient advice. Specific and up to date information about Tamoxifen Citrate. Complete Tamoxifen Citrate information from Drugs.com





Featured Reviews

Reviews Choriogonadotropin Alfa Injection

Ovidrel Drug Description OVIDREL® (choriogonadotropin alfa) Injection Prefilled Syringe FOR SUBCUTANEOUS USE DRUG DESCRIPTION Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) is a sterile liquid preparation of...
Read More  |  Review This
Reviews Cefoxitin

Mefoxin Drug Description MEFOXIN® (cefoxitin) Injection To reduce the development of drug-resistant bacteria and maintain the effectiveness of MEFOXIN* and other antibacterial drugs, MEFOXIN should be used only to treat or prevent infections...
Read More  |  Review This
Reviews Ranexa

Ranexa Drug Description Ranexa (ranolazine) Extended-Release Tablets DRUG DESCRIPTION What are the possible side effects of ranolazine (Ranexa)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Prednisolone Sodium Phosphate Oral Solution

Prednisolone Oral Solution Drug Description Prednisolone Sodium Phosphate, USP, Oral Solution 6.7 mg / 5 mL DRUG DESCRIPTION Prednisolone sodium phosphate, USP, oral solution is a dye free, colorless to light straw colored, raspberry...
Read More  |  Review This
Reviews Pepcid

Pepcid Drug Description PEPCID® (Famotidine) Tablets DRUG DESCRIPTION What are the possible side effects of famotidine, calcium, and magnesium (Dual Action Complete, Pepcid Complete)? Get emergency medical help if you have...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....